HOME >> MEDICINE >> NEWS
New data at ASCO show CAMPTOSAR is key to treating 1st line metastatic colorectal cancer

aluated the impact of adding bevacizumab to FOLFIRI and mIFL. A statistically significant improvement in OS for patients treated with FOLFIRI plus bevacizumab was seen when compared with those receiving mIFL plus bevacizumab. A total of 87 percent of patients were still alive after one year compared to 61 percent of patients given mIFL plus bevacizumab. The most frequent grade 3/4 adverse events in both arms were diarrhea, neutropenia and hypertension, with neutropenia and hypertension being higher in the FOLFIRI plus bevacizumab arm.

"This study enhances our understanding of combining FOLFIRI with the targeted agent bevacizumab as a standard treatment in first-line metastatic colorectal cancer patients," said Dr. Fuchs. "FOLFIRI plus bevacizumab significantly improved OS when compared to mIFL plus bevacizumab and both regimens were tolerable."


'"/>

Contact: Rachel Leopold
rachel.leopold@edelman.com
212-704-4433
Edelman Public Relations
5-Jun-2006


Page: 1 2

Related medicine news :

1. Study shows radiofrequency ablation highly effective in treating kidney tumors
2. Tumor cell activity may provide clues for treating breast cancer in young women
3. Mouse model points to possible new strategy for treating rare muscle disease, kidney disorders
4. Help for pediatricians in treating behavioral health problems only partially successful
5. ECP may be effective in treating Crohns disease
6. New guideline for treating Lyme disease
7. Certain combination therapy found more effective for treating malaria in African children
8. Article outlines current recommendations for treating malaria in the US
9. One pill may be better than two for treating patients with high blood pressure
10. Effectiveness of first renin inhibitor drug for treating hypertension is limited
11. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... ... SearchLight is the premier online modeling resource for fluorescence microscopists and optical system ... users during last 5 years spanning the globe, SearchLight has become a tremendously ...
(Date:4/27/2017)... DENVER (PRWEB) , ... April 27, 2017 , ... ... the nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement to ... enabled by the continuing support of the Jane and Leonard Korman Family Foundation. ...
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying to ... rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare executive open ... resume and wondering if it’s as ready as you are for a new job ...
(Date:4/27/2017)... ... 27, 2017 , ... The American Brain Foundation last night ... Neurology Award (PLINA). The couple joins a prestigious list of past PLINA winners, ... actor Michael J. Fox and former U.S. Attorney General Janet Reno. , Smith ...
(Date:4/27/2017)... ... April 27, 2017 , ... SyncDog, Inc. , the ... MobileIron Live! 2017 in Santa Clara, California. Each year, MobileIron Live! assembles ... helping organizations maximize the benefits of mobility in their operations securely. MobileIron ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
Breaking Medicine Technology:
Cached News: